Study of autoantibodies against advanced glycation endproducts of the Maillard reaction

Norie Araki, Rie Shibayama, Yumiko Ejima, Ryoji Nagai, Tomohiro Araki, Hideyuki Saya, Seikoh Horiuchi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Long-term incubation of proteins with reducing sugar proceeds to advanced glycation end products (AGEs). We previously demonstrated the presence of AGE structures in human and animal tissues, and suggested the implication of AGEs in aging and diabetic complications. In this study, we tested whether AGEs present in vivo, such as Nε-(carboxymethyl) lysine (CML) adduct, could serve as immunogens for generating autoantibodies. Plasma samples from STZ-induced diabetic rats reacted positively with AGE-proteins as well as CML-BSA, suggesting the presence of autoantibodies against AGE-structures, particularly CML in diabetic rats; the activity of the autoantibody increased with the duration of diabetic states, reflecting the accumulation of AGE proteins in these diabetic rats. An autoantibody fraction purified from the plasma of diabetic patients showed a positive reaction to AGE-proteins as well as to CML proteins, and also to human lens proteins which are known to undergo CML modification in vivo. Patients with renal failure caused by diabetes or nondiabetic pathologies had a higher autoantibody activity against AGE structures than that in normal subjects or diabetic patients without renal failure. These results suggest that AGEs accumulated in vivo serve as immunological epitopes for developing autoantibodies against AGEs, particularly against a CML structure, which might be used as an indicator of diabetic nephropathy or chronic renal failure.

Original languageEnglish
Pages (from-to)49-58
Number of pages10
JournalInternational Congress Series
Volume1223
Issue numberC
DOIs
Publication statusPublished - 2001 Dec 1
Externally publishedYes

Fingerprint

Maillard Reaction
Autoantibodies
Proteins
Renal Insufficiency
Crystallins
Advanced Glycosylation End Products
Diabetic Nephropathies
Diabetes Complications
Chronic Kidney Failure
N(6)-carboxymethyllysine
Epitopes
Pathology

Keywords

  • Advanced glycation endproducts (AGEs)
  • Chronic renal failure
  • Diabetic nephropathy
  • ELISA
  • N-(carboxymethyl)lysine (CML)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Study of autoantibodies against advanced glycation endproducts of the Maillard reaction. / Araki, Norie; Shibayama, Rie; Ejima, Yumiko; Nagai, Ryoji; Araki, Tomohiro; Saya, Hideyuki; Horiuchi, Seikoh.

In: International Congress Series, Vol. 1223, No. C, 01.12.2001, p. 49-58.

Research output: Contribution to journalArticle

Araki, Norie ; Shibayama, Rie ; Ejima, Yumiko ; Nagai, Ryoji ; Araki, Tomohiro ; Saya, Hideyuki ; Horiuchi, Seikoh. / Study of autoantibodies against advanced glycation endproducts of the Maillard reaction. In: International Congress Series. 2001 ; Vol. 1223, No. C. pp. 49-58.
@article{5164a4e5df294fde80edf475e03027a9,
title = "Study of autoantibodies against advanced glycation endproducts of the Maillard reaction",
abstract = "Long-term incubation of proteins with reducing sugar proceeds to advanced glycation end products (AGEs). We previously demonstrated the presence of AGE structures in human and animal tissues, and suggested the implication of AGEs in aging and diabetic complications. In this study, we tested whether AGEs present in vivo, such as Nε-(carboxymethyl) lysine (CML) adduct, could serve as immunogens for generating autoantibodies. Plasma samples from STZ-induced diabetic rats reacted positively with AGE-proteins as well as CML-BSA, suggesting the presence of autoantibodies against AGE-structures, particularly CML in diabetic rats; the activity of the autoantibody increased with the duration of diabetic states, reflecting the accumulation of AGE proteins in these diabetic rats. An autoantibody fraction purified from the plasma of diabetic patients showed a positive reaction to AGE-proteins as well as to CML proteins, and also to human lens proteins which are known to undergo CML modification in vivo. Patients with renal failure caused by diabetes or nondiabetic pathologies had a higher autoantibody activity against AGE structures than that in normal subjects or diabetic patients without renal failure. These results suggest that AGEs accumulated in vivo serve as immunological epitopes for developing autoantibodies against AGEs, particularly against a CML structure, which might be used as an indicator of diabetic nephropathy or chronic renal failure.",
keywords = "Advanced glycation endproducts (AGEs), Chronic renal failure, Diabetic nephropathy, ELISA, N-(carboxymethyl)lysine (CML)",
author = "Norie Araki and Rie Shibayama and Yumiko Ejima and Ryoji Nagai and Tomohiro Araki and Hideyuki Saya and Seikoh Horiuchi",
year = "2001",
month = "12",
day = "1",
doi = "10.1016/S0531-5131(01)00441-1",
language = "English",
volume = "1223",
pages = "49--58",
journal = "International Congress Series",
issn = "0531-5131",
publisher = "Elsevier BV",
number = "C",

}

TY - JOUR

T1 - Study of autoantibodies against advanced glycation endproducts of the Maillard reaction

AU - Araki, Norie

AU - Shibayama, Rie

AU - Ejima, Yumiko

AU - Nagai, Ryoji

AU - Araki, Tomohiro

AU - Saya, Hideyuki

AU - Horiuchi, Seikoh

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Long-term incubation of proteins with reducing sugar proceeds to advanced glycation end products (AGEs). We previously demonstrated the presence of AGE structures in human and animal tissues, and suggested the implication of AGEs in aging and diabetic complications. In this study, we tested whether AGEs present in vivo, such as Nε-(carboxymethyl) lysine (CML) adduct, could serve as immunogens for generating autoantibodies. Plasma samples from STZ-induced diabetic rats reacted positively with AGE-proteins as well as CML-BSA, suggesting the presence of autoantibodies against AGE-structures, particularly CML in diabetic rats; the activity of the autoantibody increased with the duration of diabetic states, reflecting the accumulation of AGE proteins in these diabetic rats. An autoantibody fraction purified from the plasma of diabetic patients showed a positive reaction to AGE-proteins as well as to CML proteins, and also to human lens proteins which are known to undergo CML modification in vivo. Patients with renal failure caused by diabetes or nondiabetic pathologies had a higher autoantibody activity against AGE structures than that in normal subjects or diabetic patients without renal failure. These results suggest that AGEs accumulated in vivo serve as immunological epitopes for developing autoantibodies against AGEs, particularly against a CML structure, which might be used as an indicator of diabetic nephropathy or chronic renal failure.

AB - Long-term incubation of proteins with reducing sugar proceeds to advanced glycation end products (AGEs). We previously demonstrated the presence of AGE structures in human and animal tissues, and suggested the implication of AGEs in aging and diabetic complications. In this study, we tested whether AGEs present in vivo, such as Nε-(carboxymethyl) lysine (CML) adduct, could serve as immunogens for generating autoantibodies. Plasma samples from STZ-induced diabetic rats reacted positively with AGE-proteins as well as CML-BSA, suggesting the presence of autoantibodies against AGE-structures, particularly CML in diabetic rats; the activity of the autoantibody increased with the duration of diabetic states, reflecting the accumulation of AGE proteins in these diabetic rats. An autoantibody fraction purified from the plasma of diabetic patients showed a positive reaction to AGE-proteins as well as to CML proteins, and also to human lens proteins which are known to undergo CML modification in vivo. Patients with renal failure caused by diabetes or nondiabetic pathologies had a higher autoantibody activity against AGE structures than that in normal subjects or diabetic patients without renal failure. These results suggest that AGEs accumulated in vivo serve as immunological epitopes for developing autoantibodies against AGEs, particularly against a CML structure, which might be used as an indicator of diabetic nephropathy or chronic renal failure.

KW - Advanced glycation endproducts (AGEs)

KW - Chronic renal failure

KW - Diabetic nephropathy

KW - ELISA

KW - N-(carboxymethyl)lysine (CML)

UR - http://www.scopus.com/inward/record.url?scp=48449099431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48449099431&partnerID=8YFLogxK

U2 - 10.1016/S0531-5131(01)00441-1

DO - 10.1016/S0531-5131(01)00441-1

M3 - Article

AN - SCOPUS:48449099431

VL - 1223

SP - 49

EP - 58

JO - International Congress Series

JF - International Congress Series

SN - 0531-5131

IS - C

ER -